Sign In
Buy BIO
$354.54
+2.07 (+0.587%)
At Close: Aug 10, 2026
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
10:16am, Monday, 10'th Aug 2026
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security
03:59am, Monday, 10'th Aug 2026
Portuguese national security agency selects BIO-key (BKYI) and Visualforma to strengthen identity security with advanced IAM and biometric authentication.
Advanced Authentication Solutions Provider BIO-key Hosts Q2 Investor Call Friday, August 14th at 10am ET
07:59am, Friday, 07'th Aug 2026
HOLMDEL, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, will host its
BIO-key and Maktabi Tech Partner to Advance Identity Security Across Saudi Arabia's Education Sector
06:59am, Thursday, 06'th Aug 2026
BIO-key's proven IAM platform and Maktabi Tech's education market leadership bring global best practices and regional expertise to schools in Saudi Arabia
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO
03:05am, Wednesday, 05'th Aug 2026
Amundi grew its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1,763.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Co
Bio-Rad Laboratories Q2 Earnings Call Highlights
12:04am, Wednesday, 05'th Aug 2026
Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
08:20pm, Tuesday, 04'th Aug 2026
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
08:02pm, Tuesday, 04'th Aug 2026
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.
Bio-Rad Reports Second-Quarter 2026 Financial Results
04:15pm, Tuesday, 04'th Aug 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Bio-Rad Laboratories Inc (BIO) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 72/100
07:59pm, Tuesday, 28'th Jul 2026
On July 28, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 4.6% to $331.00, continuing a strong upward trend with a 52-week range of $236.73 to $343.12. This
Central Bank of Jordan Selects BIO-key for National Biometric Authentication Initiative
02:59am, Tuesday, 28'th Jul 2026
Central Bank of Jordan Selects BIO-key for National Biometric Authentication, Aiming to Advance Biometric Authentication Across Jordan's Financial Sector
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100
06:58pm, Thursday, 23'rd Jul 2026
On July 23, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 3.4%, bringing the current price to $316.38. The stock has exhibited a 52-week range between $236.7
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
09:00am, Thursday, 23'rd Jul 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology
